current_report_2026-1

GLP-1s AT A CROSSROADS: STEERING ACCESS, OUTCOMES & COST Once considered niche treatments for diabetes, GLP-1 medications have rapidly gained traction as both a front-line diabetes management drug and mainstream obesity interventions, with usage surging 300% in just a few years! In 2022, the American Diabetes Association (ADA) moved GLP1’s to a front-line drug meaning diabetic patients were no longer required to try a different medication first. As more than one-third of U.S. adults meet clinical criteria for GLP-1 use, employers, payers and providers face urgent questions: How sustainable is the current trajectory? What are the true clinical and economic returns? And how should coverage evolve in 2025 and beyond? Key Takeaways:

Q Understand the scale and drivers of GLP-1 adoption Q Evaluate the economic impact on employers and payers Q Assess coverage gaps and equity implications Q Forecast the future of GLP-1 strategy in employer plans

ACCESS ON DEMAND NOW 

26

ANALYSIS

COMPLIANCE

CORPSYN.COM

EDUCATION